The SCAA identifies and unites cardiac arrest survivors, those at risk of Sudden Cardiac Death, and those interested in advocating for SCAA issues in their communities and beyond.
Overview
Vicor Technologies, Inc. (OTCBB: VCRT) creates innovative, non-invasive diagnostics based on its patented PD2i® nonlinear algorithm, a new vital sign which accurately determines the likelihood of pathological events in specific populations. Vicor is currently in the process of commercializing its first three products:
- The PD2i-VS™ (Vital Sign), which quickly evaluates critically-injured soldiers and civilians to improve triage and survivability. The PD2i-VS™ is in ongoing trials in collaboration with the U.S. Army Institute of Surgical Research (USAISR).
- The PD2i CA™ (Cardiac Analyzer), which identifies those at risk of sudden cardiac death within the following six months.
- The PD2i Analyzer™, which measures heartrate variability in patients at rest and in response to controlled exercise and paced respiration.
The FDA has granted 510(k) marketing clearance for the PD2i Analyzer™. Existing CPT codes provide physicians with current reimbursement and thus Vicor a current source of revenue. Vicor expects additional clearances for the PD2i CA™ (for sudden cardiac death), PD2i-VS™ (for trauma triage), in 2010.
Vicor anticipates additional applications for other disorders and diseases for the PD2i® nonlinear algorithm and software.
Vicor Therapeutics discovers, develops and commercializes new drugs based on unique compounds Vicor scientists have isolated from hibernating animals. In animal trials, these compounds show great promise to be able to mitigate stroke, infarction, kidney failure, obesity and other medical challenges.
